Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 7/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.31 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | MTOR | P42345 | 2/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18337679 | 0.94 | AADAT (0.38) | AADATOPRK1GABRG2GABRB3GABRA5 | |
| SCHEMBL18337368 | 0.82 | AADAT (0.47) | AADATAKT1MTORIKBKBCHUK | |
| SCHEMBL18335980 | 0.82 | AADAT (0.36) | AADATOPRK1OPRM1AKT1MTOR | |
| SCHEMBL18337120 | 0.79 | AADAT (0.45) | AADATGABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL18336917 | 0.77 | AADAT (0.35) | AADATIKBKBCHUK | |
| SCHEMBL18336724 | 0.76 | AADAT (0.41) | AADATIKBKBCHUK | |
| SCHEMBL18336883 | 0.76 | AADAT (0.47) | AADATIKBKBCHUK | |
| SCHEMBL18336952 | 0.76 | AADAT (0.37) | AADATGABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL18336680 | 0.76 | AADAT (0.34) | AADATGABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL18337074 | 0.75 | AADAT (0.49) | AADATIKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3683222-B1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-3683222-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-10065972-B2 | Bicyclic or tricyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-09-04 | — | — | US | disclosed |
| EP-3135674-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | CBR3, CBR1, CYCS | AADAT 3986/4885OPRK1 301/4885GABRG2 2483/4885 |
| US-10065972-B2 | Bicyclic or tricyclic heterocyclic compound | CBR3, CBR1, CYCS | AADAT 4071/4885OPRK1 285/4885GABRG2 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.